Literature DB >> 20373094

[Role of immunocytology in the evaluation of patients with painless gross hematuria].

B J Schmitz-Dräger1, L-A Tirsar, C Schmitz-Dräger, J Dörsam, T Ebert, E Bismarck.   

Abstract

OBJECTIVE: Gross hematuria is a highly worrisome episode in a patient's history mainly due to the fact that the prevalence of bladder cancer is significant in this group of patients. In this prospective study the role of immunocytology in the evaluation of patients with gross hematuria was investigated.
MATERIALS AND METHODS: Ucyt is an immunocytological assay based on microscopic detection of tumor-associated antigens on urothelial cells. The study included 103 consecutive patients with a first episode of painless gross hematuria without prior transitional cell carcinoma. Urine samples were obtained from all patients and examined cytologically and immunocytologically.
RESULTS: Clinical assessment by physical examination, laboratory tests, endoscopy, and imaging modalities yielded urothelial cancer in 22 cases (21%). Further diagnoses were BPH (30%), inflammation (10%), urolithiasis (7%), and"further conditions" (16%). In 17 patients the reasons for hematuria were not determined. For cystoscopy, immunocytology, and conventional urine cytology a sensitivity of 89 (excluding UUT), 86, and 45% was observed. Specificity was 94, 82, and 89%, respectively. Two and three bladder tumors were not detected by cystoscopy and immunocytology, respectively.
CONCLUSIONS: The combination of cystoscopy and immunocytology yielded 100% sensitivity, while combining cystoscopy and cytology only marginally improved the sensitivity of cystoscopy alone. Since sensitivity appears to be of key relevance in the assessment of patients with gross hematuria, the authors suggest the addition of a sensitive noninvasive test to the diagnostic armamentarium in this situation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373094     DOI: 10.1007/s00120-010-2248-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  14 in total

1.  The BTA stat test is nonspecific for hematuria: an experimental hematuria model.

Authors:  Omer Oge; Didem Kozaci; Hakan Gemalmaz
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

2.  Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.

Authors:  Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Journal:  Urology       Date:  2005-12       Impact factor: 2.649

Review 3.  Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.

Authors:  M Rodgers; J Nixon; S Hempel; T Aho; J Kelly; D Neal; S Duffy; G Ritchie; J Kleijnen; M Westwood
Journal:  Health Technol Assess       Date:  2006-06       Impact factor: 4.014

4.  Detection of bladder cancer using a point-of-care proteomic assay.

Authors:  H Barton Grossman; Edward Messing; Mark Soloway; Kevin Tomera; Giora Katz; Yitzhak Berger; Yu Shen
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

5.  The role of the bladder tumour antigen test in the management of gross haematuria.

Authors:  T W Chong; C Cheng
Journal:  Singapore Med J       Date:  1999-09       Impact factor: 1.858

6.  Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.

Authors:  Brian J Yoder; Marek Skacel; Ryan Hedgepeth; Denise Babineau; James C Ulchaker; Louis S Liou; Jennifer A Brainard; Charles V Biscotti; J Stephen Jones; Raymond R Tubbs
Journal:  Am J Clin Pathol       Date:  2007-02       Impact factor: 2.493

7.  Role of ultrasonography in screening for urological malignancies in patients presenting with painless haematuria.

Authors:  S K Yip; W C Peh; P C Tam; J H Li; C H Lam
Journal:  Ann Acad Med Singap       Date:  1999-03       Impact factor: 2.473

8.  Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark.

Authors:  Yves Fradet; Campbell Lockhard
Journal:  Can J Urol       Date:  1997-09       Impact factor: 1.344

9.  [Analyses of the role of immunocytology in the differential diagnosis of patients with asymptomatic microhematuria].

Authors:  B J Schmitz-Dräger; L-A Tirsar; C Schmitz-Dräger; B Beiche; E Bismarck; T Ebert
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

10.  Comparison of ImmunoCyt, UroVysion, and urine cytology in detection of recurrent urothelial carcinoma: a "split-sample" study.

Authors:  Peggy S Sullivan; Farzad Nooraie; Hope Sanchez; Sharon Hirschowitz; Mary Levin; P Nagesh Rao; Jianyu Rao
Journal:  Cancer       Date:  2009-06-25       Impact factor: 6.860

View more
  1 in total

Review 1.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.